Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

KYTH 74.98
price chart
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
What's happening: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) soared higher by as much as 20% ahead of a key FDA advisory panel committee meeting next week.
FDA staff backs injection to reduce double chin  Reuters
Why Kythera Biopharmaceuticals, Inc. Stock Soared Today
What: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) shot up by 22% today after the company agreed to sell itself to Botox-maker Allergan (NYSE:AGN) for $75 per share, or $2.1 billion.
Allergan to Acquire KYTHERA Biopharmaceuticals  PR Newswire (press release)
Sell Kythera (KYTH) Stock, Another Biotech Ripoff
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) stock was halted Monday as an independent advisory committee reviewed its double-chin treatment, ATX-101.
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock  GlobeNewswire (press release)
Kythera Biopharmaceuticals Inc's (KYTH) Double-Chin Treatment Backed By ...  Bidness ETC
Allergan (AGN), KYTHERA Biopharma (KYTH) Enter Amended Merger; Will Now be All ...
Allergan (NYSE: AGN) and KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) announced that they have amended and restated their merger agreement with respect to Allergan's pending acquisition of KYTHERA to provide for all-cash consideration to ...
Allergan Changes Its $2.1 Billion Deal for Kythera to All Cash  Wall Street Journal
What to Expect From Allergan Earnings  24/7 Wall St.
Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
What: Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH), a clinical-stage biopharmaceutical company developing prescription products targeted at the aesthetic medicine market, jumped by as much as 12% after the company announced it had ...
Kythera Regains ATX-101 from Bayer
Kythera Regains ATX-101 from Bayer - Analyst Blog  NASDAQ
Related articles »  
Hedge Funds Sentiment Indicator of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH ...
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) hedge funds sentiment decreased to 2.04 in Q2 2015. Its down -0.54, from 2.58 in 2015Q1.
Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA ...
WESTLAKE VILLAGE, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) announced today that the U.S.
Double-Chin Drug From Kythera Wins U.S. FDA Approval  Bloomberg
Kythera Wins FDA Approval for Double-Chin Treatment  Wall Street Journal
Why Allergan Plc Just Disclosed Huge New Kythera Biopharmaceuticals Inc Stake
Allergan Plc has filled a SC 13D form regarding Kythera Biopharmaceuticals Inc 74.98 0.00 % . Filing Link: 000119312515239534.
Leerink Downgrades Kythera, Says Allergan Deal Likely To Close At $75 Mark  Benzinga
Chin up: Allergan looks to fat-busting drug with $2.1bn Kythera deal
Morgan & Morgan Announces the Investigation of KYTHERA Biopharmaceuticals, Inc ...
NEW YORK, June 19, 2015 /PRNewswire/ -- Morgan & Morgan announces that it is investigating potential claims against the board of directors of KYTHERA Biopharmaceuticals, Inc. ("KYTHERA" or the "Company") (NASDAQ: KYTH) concerning the proposed ...
KYTHERA BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P ...  Business Wire (press release)
Kythera Biopharmaceuticals Stock Climbs On Acquisition News  CNA Finance (press release)
The Chief Commercial Officer of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH ...
Shareholder, Elisabeth Sandoval is the Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 74.98 0.00 % 's insider that made a sale of shares of Kythera Biopharmaceuticals Inc, 83,122 to be precise. The unloaded shares were based on a stock price per share ...
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling ...  Insider Trading Report
An Insider Elisabeth Sandoval Sold 83122 shares of Kythera ...